Trading in Noven Common Stock Halted; FDA Advisory Committee Meeting Today on Daytrana(TM)
Posted on: Friday, 2 December 2005, 09:00 CST
Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) announced that NASDAQ has halted trading of Noven common stock effective this morning, December 2, 2005. The Psychopharmacologic Drugs Advisory Committee to the U.S. Food and Drug Administration (FDA) meets today to review and discuss the amended New Drug Application for Daytrana(TM) (methylphenidate transdermal system).
Daytrana(TM), licensed globally to Shire plc, is an investigational transdermal patch designed for once-daily use to treat attention deficit hyperactivity disorder (ADHD) in children aged 6 to 12 years.
Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Noven's prescription patches are sold in over 30 countries, and a range of new patches are being developed in collaboration with Shire plc, Novartis Pharma AG, P&G Pharmaceuticals, Endo Pharmaceuticals Inc. and others. See http://www.noven.com for additional information.
Source: Business Wire
Related Articles
- Hisamitsu Pharmaceutical Completes Acquisition of Noven Pharmaceuticals
- Hisamitsu Pharmaceutical Announces Expiration of Subsequent Offering Period and Completion of Tender Offer for Outstanding Shares of Noven Pharmaceuticals
- Hisamitsu Pharmaceutical Announces Expiration of Initial Tender Offer Period for Outstanding Shares of Noven Pharmaceuticals and Commencement of Subsequent Offering Period
- Par Pharmaceutical & Aveva Drug Delivery Systems Receive Final Approval to Market Generic Catapres TTS(R)
- Hisamitsu Pharmaceutical Announces Expiration of HSR Waiting Period for Its Proposed Acquisition of Noven Pharmaceuticals
- Hisamitsu Pharmaceutical Co., Inc. Begins Tender Offer for All Outstanding Shares of Noven Pharmaceuticals, Inc.
- Encapsulation Systems Previews the U-Strip(TM) Insulin Patch, the Next Generation of Transdermal Drug Delivery for the Treatment of Diabetes
- The Use Of Transdermal Drug Delivery In Depression And Attention Deficit Hyperactivity Disorder Are Poised To Provide Substantial Growth For The Industry
- Poor Results for King Pharmaceuticals' Ramipril Drug
- Vyteris Announces Positive Results in Two Phase I Clinical Trials for Treatment of Infertility; Data Indicate Actyve(TM) Transdermal Drug Delivery Achieves Therapeutic Levels Of A Peptide Used For Treatment Of Infertility In Humans
 |
 |
User Comments (0)
RSS Feeds